Clearing a disease's signature biological biomarker does not guarantee functional clinical improvement.
Therapies that successfully neutralize underlying biological markers of damage or disease expression frequently fail to demonstrate real-world clinical or functional benefits in slowly progressing conditions.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Although pelacarsen successfully cleared its primary genetic biomarker target, it failed to translate that molecular change into any actual reduction in cardiovascular events.
Although pelacarsen successfully achieved its biological biomarker targets by dramatically reducing Lp(a), it failed to deliver any real-world cardiovascular outcomes.
Despite achieving large, sustained reductions in the disease's target serum TTR protein, the drug failed to show real-world clinical or survival benefit over the existing standard of care.
Despite successfully clearing the target mutant huntingtin protein biomarker, tominersen failed to provide any functional clinical benefits for Huntington's patients.
Detection performance is a proxy that cannot substitute for demonstrated mortality benefit at the regulatory gate.